This goal of this open label study is to evaluate the safety and tolerability of a single intra-articular administration of ABR1 in adults with knee osteoarthritis with a KL grade from 2 to 4. The primary questions it aims to answer are:
1. Is ABR1 safe to use as an intraarticular injection for participants with knee osteoarthritis? 2. What medical problems do participants have after receiving a single injection of ABR1?
Participants will receive a single injection of ABR1 to the knee with osteoarthritis. Participants will
1. Keep a stable pain treatment regimen 2. Visit the clinic at 1 week, 4 weeks, 8 weeks, and 12 weeks post injection 3. Keep a diary of their symptoms and number of times they use a rescue medication for their knee pain.
Male or female at least 40years of age
Knee OA with Kellgren-Lawrence (KL) Grade 2 to 4 of the target knee on X-ray
Inadequate pain relief with 1st line treatment, consisting of any of the following
conservative non-pharmacological treatment AND/OR
Pregnant or lactating
Other significant knee pathologies of target knee from medical history or radiographic method(s)
Severe malalignment > 10 degree in the target knee (either varus or valgus) measured using standardized knee x-ray at screening or based on previous medical records
Severe inflammatory arthritis or other joint disease with warm, red, and swollen knee in the target knee